Nanotech Plus, LLC - The Bio-Pharmaceutical Industry

The industry has had significant successes. Pharmaceuticals have greatly reduced the impact of cardiovascular disease, rheumatoid arthritis, blood borne cancers and numerous infectious diseases globally. Yet, new health care challenges continue to crop up, especially in infectious disease. (See the News and Events page.) The incidence and fatality rate of solid organ cancers remains high and for some types of cancers, continues to increase. Mental health care has made little progress in decades, and a high percentage of the population remain untreated, while Alzheimer's disease and other forms of senile dementia consume enormous resources at the end of life (See: "Possible therapies of Parkinson’s disease: A review"). Thus, new pharmaceuticals are needed to continue to improve the quality of life and to reduce the economic burden of aging.

Today, bio-pharmaceutical companies are dealing with a number of challenges and opportunities that will determine their future success or failure. Commercial and scientific challenges include:

Market access
Global competition
Current depressed share prices, especially for smaller firms
Mergers and acquisitions of both small and large companies
Start-up company funding requirements
Costly and extensive clinical trials.

It is fair to assume that a host of other issues will also shape the future of the industry. Understanding the competitive, scientific, and regulatory landscape will be essential for companies to ensure their success. We have helped several firms in this space with projects that have ranged from a financial evaluation of a facility which lead to a client being able to raise money from investors to pricing studies on potential drugs.